Department of Neurosurgery, University of Colorado School of Medicine, Aurora, Colorado.
Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado.
Neurosurgery. 2019 Mar 1;84(3):687-695. doi: 10.1093/neuros/nyy098.
The Neurologic Assessment in Neuro-Oncology (NANO) scale is a standardized objective metric designed to measure neurological function in neuro-oncology. Current neuroradiological evaluation guidelines fail to use specific clinical criteria for progression.
To determine if the NANO scale was a reliable assessment tool in glioblastoma (GBM) patients and whether it correlated to survival.
Our group performed a retrospective review of all patients with newly diagnosed GBM from January 1, 2010, through December 31, 2012, at our institution. We applied the NANO scale, Karnofsky performance score (KPS), Eastern Cooperative Oncology Group (ECOG) scale, Macdonald criteria, and the Response Assessment in Neuro-Oncology (RANO) criteria to patients at the time of diagnosis as well as at 3, 6, and 12 mo.
Initial NANO score was correlated with overall survival at time of presentation. NANO progression was correlated with decreased survival in patients at 6 and 12 mo. A decrease in KPS was associated with survival at 3 and 6 mo, an increase in ECOG score was associated only at 3 mo, and radiological evaluation (RANO and Macdonald) was correlated at 3 and 6 mo. Only the NANO scale was associated with patient survival at 1 yr. NANO progression was the only metric that was linked to decreased overall survival when compared to RANO and Macdonald at 6 and 12 mo.
The NANO scale is specific to neuro-oncology and can be used to assess patients with glioma. This retrospective analysis demonstrates the usefulness of the NANO scale in glioblastoma.
神经肿瘤学中的神经评估（NANO）量表是一种标准化的客观指标，旨在测量神经肿瘤学中的神经功能。目前的神经影像学评估指南未能使用特定的临床标准来判断进展。
确定 NANO 量表是否是胶质母细胞瘤（GBM）患者的可靠评估工具，以及它是否与生存相关。
我们的小组对 2010 年 1 月 1 日至 2012 年 12 月 31 日期间在我们机构新诊断为 GBM 的所有患者进行了回顾性研究。我们在诊断时以及 3、6 和 12 个月时，应用 NANO 量表、卡氏行为状态量表（KPS）、东部肿瘤协作组（ECOG）量表、麦克唐纳标准和神经肿瘤反应评估（RANO）标准对患者进行评估。
初始 NANO 评分与患者就诊时的总生存期相关。NANO 进展与 6 个月和 12 个月时患者的生存率降低相关。KPS 下降与 3 个月和 6 个月时的生存相关，ECOG 评分增加仅与 3 个月时相关，影像学评估（RANO 和麦克唐纳）与 3 个月和 6 个月时相关。只有 NANO 量表与患者的 1 年生存率相关。与 RANO 和 Macdonald 相比，NANO 进展是 6 个月和 12 个月时唯一与总生存期降低相关的指标。
NANO 量表是神经肿瘤学特有的，可以用于评估胶质瘤患者。这项回顾性分析表明 NANO 量表在胶质母细胞瘤中的有用性。
